SLC13A5

Across TCGA pan-cancer cohorts, SLC13A5 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SLC13A5’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SLC13A5 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC13A5 is over-expressed in tumor, although a few such as LIHC and UCEC show the opposite, repressed pattern.

LIHC, UCEC, and BRCA are the cancer types where SLC13A5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC13A5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	−2.040	<.001	6	view →
UCEC	All	All	−1.084	.002	6	view →
BRCA	All	III,IV	−0.199	<.001	6	view →
KIRP	All	II,III,IV	−0.190	.003	6	view →
HNSC	All	IV	+1.172	.008	5	view →
LUSC	Male	II,III,IV	+1.156	<.001	5	view →
KICH	Male	All	−0.089	.004	5	view →
PAAD	All	All	+3.605	.007	4	view →
LUAD	All	All	+0.248	.009	4	view →
BLCA	All	III,IV	+0.140	.031	4	view →
COAD	Male	IV	+0.120	.010	4	view →
CHOL	Female	All	−6.333	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SLC13A5–LIHC

Open the LIHC breakdown →